We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Novartis caught plenty of flack with last week’s revelation that its FDA application for gene therapy Zolgensma contained manipulated data and that the company didn't inform regulators until after its approval. Now it's facing a congressional investigatio